Tigertriever Distal Vessels Registry

Rapid Medical

Status: Terminated

Conditions: Ischemic Stroke

Treatments: Device: Tigertriever

Study type: Observational

Funder types: Industry

Identifiers

NCT03871309

005-035-006-ANTR-0607

Details and patient eligibility

About

A registry study to collect data on the Tigertriever device at restoring blood flow by removing clots in M2 or distal vessels in patients experiencing acute ischemic stroke, during commercial use.

Full description

Tigertriever is a CE marked mechanical revascularization device indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset.

Enrollment: 9 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who present with acute ischemic stroke, who can be treated within 6 hours of symptoms onset, who are either refractory to or ineligible for IV t-PA treatment and intend to be treated with thrombectomy.
• Patients ≥18
• NIHSS Score of ≥2
• Angiographically confirmed occlusion in a M2 or distal (medium to small) branch that is accessible to the Tigertriever device (17 or 13) as determined by the vessel diameter (≥1mm).
• Anticipated life expectancy of at least 6 months from presentation
• Signed informed consent form by the patient or a legally acceptable representative.

Exclusion criteria

• Extended infarct - ischemic changes >1/3 MCA territory / 100 ml tissue or ASPECT score <5

  • Pre- stroke mRS ≥ 2

  • Unknown time of stroke symptom onset

  • Vessel diameter < 1mm

  • Angiographically evident extreme vessel tortuosity that may preclude the device from reaching the target area.

  • Occlusion/stenosis proximal to thrombus that precludes safe retrieval

  • Medical co-morbidities including but not limited to:

  • Uncontrolled coagulopathy such as International Normalized Ratio (INR) of > 3.0 or platelets count < 40 x109/L or APTT >50 sec

  • Serious concurrent medical illness: myocardial infarction, seizures, sepsis, uncontrolled diabetes, uncontrolled hypertension, brain tumor, renal impairment (eGFR <60).

  • Baseline glucose < 2.7 or > 22.2 mmol/L

  • Imaging features of:

    • raised intracranial pressure or significant mass effect (for example, midline shift, severe sulcal effacement, transcompartmental herniation)
    • intracranial hemorrhage
    • vascular malformation or aneurysm
    • significant vascular abnormality such as carotid dissection, complete carotid occlusion or large/medium vessel vasculitis

  • Allergy/sensitivity to nickel-titanium or contrast media

  • Females who are pregnant or lactating

  • Unable to obtain informed consent from the patient or a suitable legal representative

  • Any other contraindication to thrombectomy

Trial design

9 participants in 1 patient group

Tigertriever

Description:

Male or female patients (age ≥18) who present with an acute ischemic stroke due to a M2 or distal (medium to small) vessel occlusion confirmed by vessel imaging and treated with the Tigertriever 17 or 13 revascularization devices.

Treatment:

Device: Tigertriever